Hot Sale Anti Cancer Peptide Lanreotide CAS 108736-35-2

Hot Sale Anti Cancer Peptide Lanreotide CAS 108736-35-2

Product Name: Lanreotide
Synonyms: LANREOTIDE;AUTOGEL;BETA-(2-NAPHTHYL)-D-ALA-CYS-TYR-D-TRP-LYS-VAL-CYS-THR AMIDE;BIM-23014;ANGIOPEPTIN;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2, (DISULFIDE BOND);IPSTYL
CAS: 108736-35-2
MF: C54 H69 N11 O10 S2
MW: 1096.32
EINECS: 689-178-4
Product Categories: hormones
Mol File: 108736-35-2.mol

Lanreotide (INN) like natural growth inhibitors, lanreotide is a peptide inhibitor of many endocrine, neuroendocrine, exocrine and paracrine functions. Lanreotide is more active and has a longer duration of action than natural growth inhibitors. Its inhibitory effect on growth hormone secretion is significantly more selective than that on insulin secretion, and in 2017 the FDA approved lanreotide acetate for injection for the treatment of neuroendocrine tumors.

Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome.

Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma,a rare tumor of the pituitary gland which secretes TSH.

Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.

Lanreotide CAS 108736-35-2 Chemical Properties
Boiling point 1508.2±65.0 °C(Predicted)
density 1.40±0.1 g/cm3(Predicted)
storage temp. Keep in dark place,Sealed in dry,Store in freezer, under -20°C
pka 9.90±0.15(Predicted)

Function and Application of Lanreotide CAS 108736-35-2
Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes.

Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.

Lanreotide ,In Dec 2014 the US FDA approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).